Bausch + Lomb Receives US FDA Approval for Vyzulta for IOP Reduction in Glaucoma Patients

November 3, 2017: By Jon Swedien

Bausch

The US FDA has approved the new drug application (NDA) for Bausch + Lomb’s Vyzulta for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension, parent Valeant announced Nov. 2.

Vyzulta (latanoprostene bunod ophthalmic solution 0.024%), a nitric oxide-donating prostaglandin analog, is a once daily monotherapy.

Valeant CEO Joseph Papa said the company plans to launch Vyzulta by the end of 2017.

Nicox licensed Vyzulta to Bausch + Lomb on a global basis in 2010. As a result of the approval, Nicox will receive $17.5 million from Bausch + Lomb, and Nicox will make a $15 million payment to Pfizer under a previous license agreement, Valeant said.

Vyzulta’s approval was delayed twice because of problems at Bausch + Lomb’s manufacturing plant in Tampa, Florida. The FDA held up several ophthalmic drug candidates over plant concerns in 2016 and 2017.

Valeant resolved its issues, allowing the regulatory process to proceed.

In multiple clinical studies, Vyzulta outperformed timolol and latanoprost in lowering IOP, the company said.

Previously known as Vesneo, the drug was renamed Vyzulta in January.

The most common ocular adverse events associated with Vyzulta include conjunctival hyperemia, eye irritation, eye pain, and instillation site pain, Valeant said. Increased pigmentation of the iris and periorbital tissue and growth of eyelashes also can occur, Valeant said.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Ellex Raises $17.7 Million in Private Placement

Genentech’s Lampalizumab Fails Second Phase III Study in Geographic Atrophy

Judge Declares Mistrial in Corruption Trial of Melgen, Menendez

Imprimis’ Q3-2017 Ophthalmic Revenues Increase 60 Percent, Total $4.9 Million

iVeena Completes Phase I/IIa Study of IVMED-10 for Post-Cataract Inflammation

RegeneRx Announces Positive Phase III Results for RGN-259 in Dry Eye

Bill Link, PhD, Joins LENSAR as Board Chairman

Apellis Prices $150 Million Initial Public Offering

Oculentis Recalls Lentis IOLs in Philippines Due to Reports of Postoperative Opacification

Valeant Reports 1 Percent Growth for Bausch + Lomb Segment in Q3-2017

Tivanisiran is Generic Name for Sylentis’ Dry Eye Candidate

Alimera’s Q3-2017 Revenues Increased 18 Percent; Company Sees Expanded Market for Iluvien

Iridex’ Revenues Increase 11 Percent in Q3-2017; 111 Cyclo G6 Systems, 7,800 G6 Probes Shipped

Glaukos’ Net Sales Increase 37 Percent in Q3-2017

Regeneron’s US Eylea Sales Increase 12 Percent in Q3-2017

Second Sight Reports Q3-2017 Net Sales of $1.6 Million, New $122,500 CMS Rate for Argus II

Tear Film Innovations, Exicure, Genisphere Complete Financing Rounds

Opternative Sues Warby Parker Over Online Eye Exams

Bausch + Lomb Receives US FDA Approval for Vyzulta for IOP Reduction in Glaucoma Patients

Allergan Plans Cost Cuts, Takes Impairment Charge as Restasis Generics Loom

Coming soon

2017 Dry Eye Products Report: A Global Market Analysis for 2016 to 2022